Samuel Kintz's Planned Sale of Enliven Therapeutics Shares

Samuel Kintz, an officer of Enliven Therapeutics, Inc., has filed a notice of intent to sell 12,500 common shares of the company. The shares, acquired as founder shares on September 1, 2019, are to be sold pursuant to a 10b5-1 selling plan adopted on November 15, 2024. The sale is scheduled for October 17, 2025, with an aggregate market value of $271,875. Additionally, Kintz has sold a total of 14,017 shares in the past three months, generating gross proceeds of $276,153.98. The sales were executed through Jefferies LLC on the Nasdaq exchange.